← Back to Screener
Rallybio Corporation Common Stock (RLYB)
Price$16.87
Value ScoreD
Growth ScoreC
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)180.38%
Price vs S&P 500 (4W)48.69%
VGM Score53.03
Market Capitalization$76.61M
All Metrics
Book Value / Share (Quarterly)$9.50
P/TBV (Annual)0.54x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.21
Price vs S&P 500 (YTD)152.45%
Net Profit Margin (TTM)-911.07%
EPS (TTM)$-1.37
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-1.37
EPS (Annual)$-1.59
ROI (Annual)-15.49%
Cash / Share (Quarterly)$8.85
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-14.42%
Revenue Growth TTM (YoY)1.18%
EBITD / Share (TTM)$-5.72
ROE (5Y Avg)-49.11%
Operating Margin (TTM)-3777.86%
Cash Flow / Share (Annual)$-5.64
P/B Ratio1.52x
P/B Ratio (Quarterly)0.94x
Net Income / Employee (Annual)$-641,300
EV / Revenue (TTM)41.16x
ROA (TTM)-13.28%
EPS Incl Extra (Annual)$-1.59
Current Ratio (Annual)14.50x
Quick Ratio (Quarterly)12.69x
3-Month Avg Trading Volume0.24M
52-Week Price Return467.06%
Revenue / Employee (TTM)$61,300
Tangible BV / Share (Quarterly)$3.27
P/S Ratio (Annual)89.29x
Asset Turnover (Annual)0.01x
52-Week High$16.00
EPS Excl Extra (Annual)$-1.59
26-Week Price Return196.31%
Quick Ratio (Annual)13.56x
13-Week Price Return112.65%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.92x
Enterprise Value$35.31M
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$61,300
Pretax Margin (Annual)-1046.39%
Cash / Share (Annual)$10.36
3-Month Return Std Dev144.76%
Net Income / Employee (TTM)$-558,400
ROE (Last FY)-15.49%
EPS Basic Excl Extra (Annual)$-1.59
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.37
ROI (TTM)-14.39%
P/S Ratio (TTM)89.29x
Revenue / Share (Annual)$0.15
Tangible BV / Share (Annual)$4.47
Price vs S&P 500 (52W)438.85%
Year-to-Date Return163.39%
5-Day Price Return-8.94%
EPS Normalized (Annual)$-1.59
ROA (5Y Avg)-45.30%
Net Profit Margin (Annual)-1046.39%
Month-to-Date Return61.02%
Cash Flow / Share (TTM)$-1.80
EBITD / Share (Annual)$-6.01
Operating Margin (Annual)-3955.48%
ROI (5Y Avg)-49.11%
EPS Basic Excl Extra (TTM)$-1.37
P/TBV (Quarterly)0.75x
P/B Ratio (Annual)0.50x
Pretax Margin (TTM)-911.07%
Book Value / Share (Annual)$10.97
Price vs S&P 500 (13W)102.90%
Beta-0.84x
Revenue / Share (TTM)$0.15
ROE (TTM)-14.39%
52-Week Low$2.16
vGradeD
gGradeC
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.46est. -1.22
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.80
3.80
2.29
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RLYBRallybio Corporation Common Stock | D | C | A | $16.87 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Rallybio is a clinical-stage biotechnology company developing therapeutic candidates for severe, rare diseases driven by complement dysregulation and blood disorders. Its lead program, RLYB116, is a C5 inhibitor targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. The company's pipeline also includes RLYB332, a long-acting antibody in preclinical development for iron overload disorders.